Association between affective-cognitive symptoms of depression and exacerbation of Crohn's disease

American Journal of Gastroenterology

Volumn 111, Issue 6, 2016, Pages 864-870

  Gaines, Lawrence S ^a   Slaughter, James C ^a   Horst, Sara N ^a   Schwartz, David A ^a   Beaulieu, Dawn B ^a   Haman, Kirsten L ^a   Wang, Li ^a   Martin, Christopher F ^b   Long, Millie D ^b   Sandler, Robert S ^b   Kappelman, Michael D ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL SURGERY; ADULT; AGE; ARTICLE; BODY MASS; COGNITIVE DEFECT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DEMOGRAPHY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; GENDER; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MOOD DISORDER; PATIENT COMPLIANCE; PATIENT HISTORY OF SURGERY; PREVALENCE; PRIORITY JOURNAL; RACE; RECURRENCE RISK; SLEEP QUALITY; SMOKING; COMPLICATION; DISEASE EXACERBATION; PROSPECTIVE STUDY; PSYCHOLOGY; QUESTIONNAIRE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; CROHN DISEASE; DEPRESSION; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; MALE; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84962708903     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.98     Document Type: Article

References (23)

1. Loftus EV, Schoenfl ed P, Sandborn WJ. The epidemiology and natural history of Crohn?s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60
2. Walker JR, Eidger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008; 103: 1989-97.
3. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with infl ammatory bowel disease: a prospective 18-month follow up study. Psychosom Med 2004; 66: 79-84
4. Mardini HE, Kip KE, Wilson JW. Crohn?s disease: a two year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004; 49: 492-7.
5. Szigethy EM, Youk AO, Benhavon D, et al. Depression subtypes in pediatric infl ammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58: 574-81.
6. Long MD, Kappelman MD, Martin CF, et al. Development of an internetbased cohort of patients with infl ammatory bowel diseases (CCFAPartners): methodology and initial results. Infl amm Bowel Dis 2012; 18: 2099-106.
7. Pilkonis PA, Seung WC, Reise SP, et al. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS): depression, anxiety, and anger. Assessment 2011; 18: 263-83.
8. Thia K, Faubion WA, Loftus EV, et al. Short CD AI: development and validation of a shortened and simplifi ed Crohn's disease activity index. Infl amm Bowel Dis 2011; 17: 105-11.
9. Loftus EV. Epidemiology of infl ammatory bowel disease. In: Talley NK, Locke GR, Moayyed P, et al. (eds). GI Epidemiology: Diseases and Clinical Methodology, 2nd edn. John Wiley: Chicester, West Sussex, UK, 2014, pp 273-84.
10. Morisky DD, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1987; 24: 67-74
11. Harrell FE, Slaughter JC. Information loss. In: Introduction to Biostatistics for Biomedical Research, Chapter 7, Department of Biostatistics, 2015, Available at: Biostat.mc.vanderbilt.edu/ClinStat
12. Royston P, Altman DG, Sauerbrei W. Dicohotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-41.
13. Zhang CK, Hewett J, Hemming J, et al. The Influence of depression on quality of life in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2013; 19: 1732-9.
14. Ray I, Stiles R, Domenico H, et al. Cost of outpatient treatment of Crohn?s disease with comorbid depression in an academic medical center. Presented at: Digestive Disease Week, 2013. Orlando, FL, USA
15. Shale MJ, Riley A. Studies of compliance with delayed-release mesalazine therapy in patients with infl ammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
16. Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- And long-Term outcome of Crohn?s disease treatment with infl iximab. Aliment Pharmacol Ther 2005; 22: 101-10.
17. Ananthakrishanan AN, Khalili H, Pan A, et al. Association between depressive symptoms and incidence of Crohn?s disease and ulcerative colitis: results from the Nurses? Health Study. Clin Gastroenterol Hepatol 2013; 11: 57-62
18. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011; 13: 7-23.
19. Groenewold NA, Doombos B, Zuidesma M, et al. Comparing cognitive and somatic symptoms of depression in myocardial infarction patients and depressed patients in primary and mental health care. PLosOne 2013; 8: e53859.
20. Wiltink J, Michal M, Wild PS, et al. Associations between depression and diabetes in the community: do symptom dimensions matter? Results from the Gutenberg Health Study. PLoS One 2014; 9: e 105499.
21. Kupper N, Widdershoven JW, Pedersen SS. Cognitive/aff ective and somatic/aff ective symptom dimensions of depression are associated with current and future infl ammation in heart failure patients. J Aff ect Disord 2012; 136: 567-76.
22. Rampton D. The Influence of stress on the development and severity of immune-mediated diseases. J Rheumatol Suppl 2011; 88: 43-7.
23. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalization and mucosal healing in Crohn?s disease in the SONIC trial. Gut 2014; 63: 88-95